Drugs that contain Lisdexamfetamine Dimesylate

1. List of Vyvanse drug patents

VYVANSE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(a month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Feb, 2023

(a month ago)

US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(a month ago)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(a month ago)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(4 months from now)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(4 months from now)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Aug, 2023

(4 months from now)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(4 months from now)

Market Authorisation Date: 23 February, 2007

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disor...

Dosage: CAPSULE;ORAL

How can I launch a generic of VYVANSE before it's patent expiration?
More Information on Dosage

VYVANSE family patents

688

United States

18

Australia

15

European Union

13

Japan

11

Canada

9

Korea, Republic of

8

China

5

Austria

4

Israel

4

Spain

3

Mexico

3

Brazil

2

South Africa

2

Norway

2

Germany

EA

2

EA

2

New Zealand

1

Denmark

1

Egypt

1

Hong Kong

1

Slovenia

1

Russia

1

Singapore

1

Portugal

1

Cyprus

1

Netherlands

1

Poland

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in